Search
GRI Bio Inc
GRIAdd to Watchlist
1.870USD
+0.090+5.06%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
33.24KMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+5.06%
5 Days
+2.75%
1 Month
-12.21%
6 Months
-76.15%
Year to Date
-72.94%
1 Year
+29.86%
Key Figures
1.820Open
1.890High
39.13KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
220.17%Turnover Ratio
1.780Prev. Close
1.804Low
56.08KTurnover
LossP/E Static
0.01P/B
0.00%Div Yield TTM
-141.84%ROA
80.36052wk High
1.22Volume Ratio
-10.12MNet Profit
17.77KShares
-3249.6573EPS TTM
-1.18Beta
-185.67%ROE
1.97052wk Low
4.81%Amplitude
--Gross Margin
33.24KMarket Cap
-2.64Reward/Risk
6.23%Risk Rate
TradingKey Stock Score of GRI Bio Inc
Currency: USD Updated: 2026-07-02Key Insights
GRI Bio Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 210 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 156.00.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
GRI Bio Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
GRI Bio Inc Highlights
StrengthsRisks
GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. The Company’s therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The Company is also developing a pipeline of novel type II diverse NKT agonists for the treatment of systemic lupus erythematosus. Its product candidate portfolio also includes GRI-0803 and a proprietary library of more than 500 compounds. It is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) and multiple sclerosis (MS).
Overvalued
The company’s latest PE is -0.00, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 10.85K shares, increasing 32.67% quarter-over-quarter.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
156.000
Target Price
+8664.04%
Upside Space
GRI Bio Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
GRI Bio Inc Info
GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. The Company’s therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The Company is also developing a pipeline of novel type II diverse NKT agonists for the treatment of systemic lupus erythematosus. Its product candidate portfolio also includes GRI-0803 and a proprietary library of more than 500 compounds. It is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) and multiple sclerosis (MS).
Ticker SymbolGRI
CompanyGRI Bio Inc
CEOHertz (W. Marc)
Websitehttps://www.gribio.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of GRI Bio Inc (GRI)?
The current price of GRI Bio Inc (GRI) is 1.87.
What is the symbol of GRI Bio Inc?
The ticker symbol of GRI Bio Inc is GRI.
What is the 52-week high of GRI Bio Inc?
The 52-week high of GRI Bio Inc is 80.36.
What is the 52-week low of GRI Bio Inc?
The 52-week low of GRI Bio Inc is 1.97.
What is the market capitalization of GRI Bio Inc?
The market capitalization of GRI Bio Inc is 33.24K.
Is GRI Bio Inc (GRI) currently rated as Buy, Hold, or Sell?
According to analysts, GRI Bio Inc (GRI) has an overall rating of Buy, with a price target of 156.00.
What is the Earnings Per Share (EPS TTM) of GRI Bio Inc (GRI)?
The Earnings Per Share (EPS TTM) of GRI Bio Inc (GRI) is -3410.36.